RT Journal Article
SR Electronic
T1 Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.16.24313494
DO 10.1101/2024.09.16.24313494
A1 Dehn, Jason G.
A1 Logan, Brent
A1 Shaw, Bronwen E.
A1 Devine, Steven
A1 Ciurea, Stefan O.
A1 Horowitz, Mary
A1 He, Naya
A1 Pusic, Iskra
A1 Srour, Samer A.
A1 Arai, Sally
A1 Juckett, Mark
A1 Uberti, Joseph
A1 Hill, LaQuisa
A1 Vasu, Sumithira
A1 Hogan, William J.
A1 Hayes-Lattin, Brandon
A1 Westervelt, Peter
A1 Bashey, Asad
A1 Farhadfar, Nosha
A1 Grunwald, Michael R.
A1 Leifer, Eric
A1 Symons, Heather
A1 Saad, Ayman
A1 Vogel, Jenny
A1 Erickson, Connor
A1 Buck, Kelly
A1 Lee, Stephanie J.
A1 Pidala, Joseph
YR 2024
UL http://medrxiv.org/content/early/2024/09/16/2024.09.16.24313494.abstract
AB Importance Patients requiring allogeneic hematopoietic cell transplantation have variable likelihoods of identifying an 8/8 HLA-matched unrelated donor. A Search Prognosis calculator can estimate the likelihood.Objective To determine if using a search algorithm based on donor search prognosis can result in similar incidence of transplant between patients Very Likely (>90%) vs Very Unlikely (<10%) to have a matched unrelated donor.Design This interventional trial utilized a Search Prognosis-based biologic assignment algorithm to guide donor selection. Trial enrollment from June 13, 2019-May 13, 2022; analysis of data as of September 7, 2023 with median follow-up post-evaluability of 14.5 months.Settings National multi-center Blood and Marrow Transplantation Clinical Trials Network 1702 study of US participating transplant centers.Participants Acute myeloid and lymphoid leukemias, myelodysplastic syndrome, Hodgkin’s and non-Hodgkin’s lymphomas, severe aplastic anemia, and sickle cell disease patients referred to participating transplant centers were invited to participate. 2225 patients were enrolled and 1751 were declared evaluable for this study. Patients were declared evaluable once it was determined no suitable HLA-matched related donor was available.Intervention Patients assigned to the Very Likely arm were to proceed with matched unrelated donor, while Very Unlikely were to utilize alternative donors. A third stratum, Less Likely (∼25%) to find a matched unrelated donor, were observed under standard center practices, but were not part of the primary objective.Main Outcome Cumulative incidence of transplantation by Search Prognosis armResults Evaluable patients included 1751 of which 413 (24%) were from racial/ethnic minorities. Search prognosis was 958 (55%) Very Likely, 517 (30%) Less Likely and 276 (16%) Very Unlikely. 1171 (67%) received HCT, 384 (22%) died without HCT, and 196 (11%) remained alive without HCT. Among the 1,234 patients, the adjusted cumulative incidence (95% CI) of HCT at 6-months was 59.8% (56.7-62.8) in the Very Likely group versus 52.3% (46.1-58.5) in the Very Unlikely (P=0.113).Conclusions A prospective Search Prognosis-based algorithm can be effectively implemented in a national multicenter clinical trial. This approach resulted in rapid alternative donor identification and comparable rates of HCT in patients Very Likely and Very Unlikely to find a matched unrelated donor.Trial Registration: NCT#03904134Competing Interest StatementS.J.L- Board of Directors, nmdp (uncompensated) A.S.-Consulting Fees: Sanofi and Therakos Clinical TrialNCT03904134Funding StatementSupport for this study was provided by grants #U10HL069294 and #U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute. The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHSH234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of NMDP gave ethnical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be submitted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to the National Heart, Lung, and Blood Institute (NHLBI) Data Repository within a month of peer-reviewed primary study results publication and will be accessible via standard Repository processes. https://bmtctn.net/bmt-ctn-studies